Hong Kong Hospitality Stock News

Trade wars are no longer just headlines. They are quietly reshaping where factories sit, how goods move, and which companies carry more risk when tariffs flare up. That shift creates a real opening for investors who watch how supply chains are rewired rather than only where demand comes from. This article unpacks that story and spotlights 3 stocks from our Nearshoring and Onshoring Industrial Infrastructure screener that appear positively exposed to the latest trade shock. The three stocks...

China Galaxy Securities has delivered a powerful 5 year share price run, even though the stock has fallen sharply over the past year. This puts fresh focus on whether current investors are paying a justified price for its earnings. With that backdrop, the live question is how well the present valuation lines up with what the business is actually earning today. Over the past 5 years, China Galaxy Securities has returned about 127.0%, which puts a lot of past optimism into the current share...

Yue Yuen Industrial (Holdings) reported unaudited net consolidated operating revenue of US$636,647,000 for August 2026 and US$5,217,301,000 for the year to date. The fresh monthly and year to date sales disclosure gives investors a timely read on demand trends and order flow across Yue Yuen Industrial (Holdings)' manufacturing operations. This article now considers how Yue Yuen Industrial (Holdings)' latest unaudited revenue figures may influence the broader investment narrative around the...

CITIC (SEHK:267) has drawn investor interest after its latest trading session, with the share price closing at HK$12.98 and short term performance showing mixed moves over the past week and month. Short term momentum in CITIC has eased, with the share price down 2.63% over the last session and 3.99% over the week. However, a 1-year total shareholder return of 15.59% and triple digit 3-year and 5-year total shareholder returns suggest longer term holders have still seen strong overall...

As the Asian markets navigate a complex landscape marked by geopolitical tensions and fluctuating oil prices, investors are keeping a keen eye on potential opportunities. Penny stocks, though often considered niche investments, can offer unique growth prospects when they are underpinned by solid financial health. This article will explore three such stocks that stand out for their balance sheet strength and potential for long-term success in the current economic climate.

China Coal Energy reported August 2026 data showing commercial coal production and self produced coal sales below the prior year, while several chemical products such as polyethylene and polypropylene recorded higher volumes. The mix of softer coal volumes alongside relatively resilient chemicals output signals shifting demand and capacity use within China Coal Energy's coal and coal chemicals portfolio. In the following sections we examine how China Coal Energy's investment narrative is...

By selling CN¥186m worth of Butong Group ( HKG:6090 ) stock at an average sell price of CN¥34.76 over the last year...

Just because a business does not make any money, does not mean that the stock will go down. For example, Values...

Akeso (SEHK:9926) is back in focus after presenting new overall survival data from its Phase III HARMONi-2 trial of ivonescimab versus pembrolizumab in first-line PD-L1-positive non-small cell lung cancer at WCLC 2026. Akeso’s HK$95.25 share price has drifted lower over the year to date with a decline of 15.93%, yet a 13.53% 3 month share price return and a 3 year total shareholder return of 151.98% suggest long term holders have still seen strong gains as sentiment oscillates around each new...

Venture Global and China Gas Holdings previously announced a 20-year Sales and Purchase Agreement for 0.5 million tonnes per annum of U.S. LNG from 2030, lifting China Gas's contracted LNG offtake with Venture Global to 2.5 million tonnes per year. The additional volumes deepen China Gas Holdings' access to long-term U.S. LNG and support its goal of building an international energy trading platform that links overseas supply with growing demand. We will now examine how China Gas Holdings'...

Chen Lin Education Group Holdings Limited ( HKG:1593 ) insiders who purchased shares in the last 12 months were richly...

As the Asian markets navigate a landscape marked by geopolitical tensions and fluctuating oil prices, investors are keenly observing opportunities that may arise amidst these challenges. Penny stocks, despite their somewhat outdated moniker, continue to attract attention for their potential to offer growth opportunities in smaller or emerging companies. This article will explore three such stocks that not only demonstrate financial resilience but also present intriguing possibilities for...

Last week, you might have seen that China Overseas Land & Investment Limited ( HKG:688 ) released its half-yearly...

Datang International Power Generation (SEHK:991) has drawn fresh attention after a recent price move left the share price at HK$2.645. Investors are weighing this level against the group’s substantial power generation footprint across China. Recent trading tells a mixed story. The 1 day share price return declined 1.67% and the 7 day share price return slipped 2.76%. However, Datang International Power Generation still shows a 30 day share price return of 8.62% and a year to date share price...

Markets are being rewired in real time as fresh transparency rules, tighter investor protections and shifting geopolitics reshape how capital moves across borders. That kind of structural change can reward firms that adapt early and expose laggards that do not. This article unpacks that story and profiles 3 stocks from a Global Exchanges & Market Infrastructure Providers screener that appear particularly exposed to the latest round of regulatory and geopolitical crosswinds. The stocks...

JNBY Design reported full year results to June 30, 2026, with sales of CNY 6,046.26 million and net income of CNY 997.45 million, alongside higher basic and diluted earnings per share from continuing operations compared with the prior year. The company delivered this higher full year profit while also managing board succession, as a key independent director prepares to retire and committee leadership shifts to another independent member. This article examines how JNBY Design's higher full...

The National Medical Products Administration has accepted LongBio Pharma’s Biologics License Application for LP-003, supported by Innovent Biologics (SEHK:1801) subsidiary Altruist Biologics, marking China’s first anti-IgE BLA for seasonal allergic rhinitis. For investors tracking Innovent Biologics, the latest regulatory milestone lands after a mixed stretch in the market, with the share price slipping 1.9% over the last session and 5.2% across the week, yet recording a 26.9% 90 day share...

HKBN reported that on 11 September 2026, Ling Hao stepped down as executive director, chairman and nomination committee chair, with China Mobile Hong Kong chief executive Shi Xiaoping taking over all three roles. The move brings HKBN a leader with over 25 years of telecom execution experience across network build out, operations, compliance and enterprise-facing services. This could influence how the business prioritises broadband, ICT and partnership decisions. It remains to be seen how...

Shenzhen International Holdings (SEHK:152) has completed a fresh RMB 1,000 million medium term note issuance at a 2.07% coupon and 10 year maturity, giving investors new information on its long term funding mix. Set against that new funding, Shenzhen International Holdings’ share price has been choppy. The stock is up 5.06% on a 1 month share price return but down 38.50% on a year to date share price return, while the 3 year total shareholder return of 30.17% contrasts with a 1 year total...

CSPC Pharmaceutical Group recently reported a cluster of R&D milestones, including multiple NMPA clinical trial approvals and a new Breakthrough Therapy Designation across neurological, oncology, ophthalmology and infectious disease programs. This run of new Parkinson’s, solid tumour, dry eye, influenza and head and neck cancer candidates points to more intensive R&D execution, a broader late stage workload and potentially higher development costs alongside a more diversified future revenue...

Henderson Land Development (SEHK:12) has drawn attention after recent share performance data showed the stock flat on the day but down over the past week, month and past 3 months. Investors are reassessing what that means for value and income potential. Viewed over a longer stretch, Henderson Land Development has a 1-year total shareholder return that is down 4.24%, even as the 3-year total shareholder return sits at 55.64%. This suggests that longer term holders have seen gains while shorter...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just cleared an important hurdle. Positive phase III data for its HER2 antibody drug trastuzumab botidotin, together with Chinese regulatory approval, now anchors a key part of the investment story. In the short term, the Sichuan Kelun-Biotech Biopharmaceutical share price has pulled back. The 1-day move is down 3.91% and the 30-day share price return is down 11.16%. However, the 90-day share price return is up 14.63% and the 3-year total...

Simcere Pharmaceutical Group (SEHK:2096) has hit two major milestones within days. Chinese regulators approved its Culevibart Injection for RSV prevention in newborns and infants, and Roche licensed SIM0660 with material upfront, milestone and royalty economics. These twin announcements have come as Simcere Pharmaceutical Group’s share price has climbed 14.59% over the past 90 days, even though the 1-year total shareholder return is down 15.46% and the 3-year total shareholder return is up...

Keymed Biosciences (SEHK:2162) has moved back into focus after signing an exclusive licensing and commercialization agreement with Aeira that covers its IL-4Ra-targeted antibody Kangyueda across Southeast and Central Asia. Recent trading has been choppy for Keymed Biosciences. The share price is up 2.60% over the past day to HK$74.95, yet the 7 day and 30 day share price returns are down 4.03% and 4.09%. The 90 day and year to date share price returns of 33.13% and 40.22% point to stronger...